Home › Malattia di Crohn › Illinois
Studi clinici su Malattia di Crohn nello stato di Illinois
18 studi su Malattia di Crohn cercano partecipanti presso sedi nello stato di Illinois.
Città nello stato di Illinois
Testo ufficiale dello studio (inglese)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- University of Chicago Medical Center ( Site 5066), Chicago
- Endeavor Health ( Site 5018), Evanston
- GI ALLIANCE - GURNEE ( Site 5003), Gurnee
In reclutamentoFase 3
Età da 16 a 80 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Midwest Digestive Health & Nutrition /ID# 285250, Des Plaines
- Gi Alliance - Glenview /ID# 283932, Glenview
- Illinois Gastroenterology Group /ID# 283933, Gurnee
- e altri 1
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Yapp, Rockford M.D. (Private Practice), Downers Grove
- GI Alliance - Glenview, Glenview
- Gastroenterology and Internal Medicine Specialists, SC, Lake Barrington
- e altri 3
In reclutamentoFase 4
Età da 18 a 80 · Tutti i sessi · Aggiornato il 30 set 2026 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- University of Chicago Medical Center /ID# 267400, Chicago
- OSF St. Francis Medical Center /ID# 266973, Peoria
- Springfield Clinic Main Campus /ID# 267434, Springfield
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06548542Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Rush University Medical Center, Chicago
In reclutamentoFase 3
Età da 18 a 70 · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Rush University Medical Center-Site Number: 8400015, Chicago
- Midwest Digestive Health and Nutrition-Site Number: 8400136, Des Plaines
- GI Alliance - Glenview-Site Number: 8400068, Glenview
- e altri 1
In reclutamentoFase 3
Età da 16 a 80 · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Illinois Gastroenterology Group d/b/a GI Alliance - Gurnee-Site Number: 8400049, Gurnee
In reclutamentoFase 3
Età da 16 a 80 · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07184944A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- Rush University Medical Center, Chicago
In reclutamentoFase 2
Età da 18 a 80 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07483073A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
- Rush University Medical Center, Chicago
In reclutamentoFase 2
Età da 18 a 80 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07483099A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- University of Chicago Medicine, Chicago
In reclutamentoFase 4
Età da 18 a 70 · Tutti i sessi · Aggiornato il 9 set 2026 · NCT06045754Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- University of Chicago Medicine, Chicago
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 7 ago 2026 · NCT05230173Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- OSF St. Francis Medical Center /ID# 262192, Peoria
In reclutamentoFase 3
Età da 2 a 17 · Tutti i sessi · Aggiornato il 24 giu 2026 · NCT06332534A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Advocate Children's Hospital Park Ridge, Park Ridge
In reclutamentoFase 3
Età da 2 a 17 · Tutti i sessi · Aggiornato il 22 giu 2026 · NCT06405087A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Advocate Children's Hospital - Park Ridge - PIN, Park Ridge
In reclutamentoFase 3
Età 2 e oltre · Tutti i sessi · Aggiornato il 7 mag 2026 · NCT05442567A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Advocate Children's Hospital Park Ridge, Park Ridge
In reclutamentoFase 3
Età da 2 a 17 · Tutti i sessi · Aggiornato il 5 mag 2026 · NCT04779320Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Northwestern University, Evanston
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 27 apr 2026 · NCT06456593A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Glenview
- Mirador Therapeutics Selected Site, Gurnee
In reclutamentoFase 2
Età da 18 a 80 · Tutti i sessi · Aggiornato il 12 mar 2026 · NCT07113522Treatment of Moderate to Severe Refractory Crohn's Disease
- Northwestern, Chicago
- University of Chicago, Chicago
In reclutamentoFase 1/2
Età da 18 a 65 · Tutti i sessi · Aggiornato il 10 dic 2025 · NCT06721962Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.